• Overview
  • Eligibility
  • More info
  • Locations

A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma (NCT00003737)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.
  • Drug: becatecarin
    Ages eligible for Study
    up to 18 Years
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    OBJECTIVES:

    - Determine the response rate to rebeccamycin analogue in children with relapsed or refractory neuroblastoma.

    - Determine the toxicity of this drug in these patients.

    - Identify and establish in vitro biologic correlates of clinical responses and toxicity of this drug in these patients.

    OUTLINE: Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.

    PROJECTED ACCRUAL: This study will accrue up to 30 patients within 1.5 years.

    1 locations

    United States (1)
    • Memorial Sloan-Kettering Cancer Center
      New York, New York, United States, 10021
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    31 December, 1998
    Updated:
    23 June, 2013
    Participants:
    30
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!